AstraZeneca plc (AZN) Ordinary US$0.25
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
London close: Stocks finish mixed as US GDP growth slows
25 April 2024 15:14
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of...
-
AstraZeneca blows past analysts' estimates for Q1
25 April 2024 08:38
(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.
-
London close: Stocks finish lower as ECB stands pat
11 April 2024 15:56
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index...
-
AstraZeneca to hike 2024 dividend by 7%
11 April 2024 07:20
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash...
-
AstraZeneca's Enhurtu cancer gets US green light for adult patients
8 April 2024 07:02
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic...
-
AstraZeneca announces positive lung cancer treatment trial results
5 April 2024 07:23
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
-
London close: Stocks turn red on return from Easter break
2 April 2024 15:22
(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week...
-
US FDA gives green light for use of AstraZeneca's Voydeya
2 April 2024 07:08
(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal...
-
AstraZeneca gets FDA approval for Ultomiris treatment
25 March 2024 07:23
(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.
-
AstraZeneca to buy US-listed Fusion Pharma for $2bn
19 March 2024 07:05
(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
-
AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn
14 March 2024 07:16
(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.
-
AstraZeneca's chemo replacement treatment moves closer to EU approval
4 March 2024 07:18
(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment...
Company announcements Announcements
-
1st Quarter Results
25 April 2024 07:00
AstraZeneca
-
Result of AGM
11 April 2024 17:30
AstraZeneca
-
AstraZeneca increases 2024 dividend by 7%
11 April 2024 07:00
AstraZeneca
-
Enhertu approved in US for HER2+ solid tumours
8 April 2024 07:00
AstraZeneca
-
Imfinzi improved OS & PFS in limited-stage SCLC
5 April 2024 07:00
AstraZeneca
-
Total Voting Rights
2 April 2024 15:00
AstraZeneca
-
Voydeya approved in US
2 April 2024 07:05
AstraZeneca
-
FDA accepts Dato-DXd BLA for breast cancer
2 April 2024 07:00
AstraZeneca
-
Ultomiris approved in the US for NMOSD
25 March 2024 07:00
AstraZeneca
-
AstraZeneca to acquire Fusion
19 March 2024 07:00
AstraZeneca
-
AstraZeneca to acquire Amolyt
14 March 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
12 March 2024 11:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.